Stage III non-small-cell lung cancer
an overview of treatment options
Informazioni aggiuntive
Autori
Petrella F.,
Rizzo S. M. R.,
Attili I.,
Passaro A.,
Zilli T.,
Martucci F.,
Bonomo L.,
Del Grande F.,
Casiraghi M.,
De Marinis F.,
Spaggiari L.
Tipo
Articolo pubblicato in rivista scientifica
Anno
2023
Lingua
Inglese
Sommario
Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage—mainly stage III—consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer.
Parole chiave
Lung cancer, Stage III, Surgery, Medical treatment, Radiotherapy
Periodico
Current oncology
Volume
30
Numero ( Mese )
3
Pagine (o numero dell’articolo)
3160-3175
Diffusione
Licenza
CC BY
Visibilità
Pubblico
Status open access
Gold
